


Handbook of Pharmaceutical Excipients

Sixth edition

Edited by
Raymond C Rowe, Paul J Sheskey and Marian E Quinn



PP
Pharmaceutical Press



DOCKET
A L A R M

Find authenticated court documents without watermarks at docketalarm.com.

Handbook of Pharmaceutical Excipients

Handbook of Pharmaceutical Excipients

SIXTH EDITION

Edited by

Raymond C Rowe BPharm, PhD, DSC, FRPharmS, FRSC, CPhys, MInstP

Chief Scientist

Intelligensys Ltd, Stokesley, North Yorkshire, UK

Paul J Sheskey BSc, RPh

Application Development Leader

The Dow Chemical Company, Midland, MI, USA

Marian E Quinn BSc, MSc

Development Editor

Royal Pharmaceutical Society of Great Britain, London, UK



London • Chicago

No 1012

Published by the Pharmaceutical Press

An imprint of RPS Publishing

1 Lambeth High Street, London SE1 7JN, UK
100 South Atkinson Road, Suite 200, Grayslake, IL 60030-7820, USA

and the American Pharmacists Association

2215 Constitution Avenue, NW, Washington, DC 20037-2985, USA

© Pharmaceutical Press and American Pharmacists Association 2009

(PP) is a trade mark of RPS Publishing

RPS Publishing is the publishing organisation of the Royal Pharmaceutical Society of Great Britain

First published 1986
Second edition published 1994
Third edition published 2000
Fourth edition published 2003
Fifth edition published 2006
Sixth edition published 2009

Typeset by Data Standards Ltd, Frome, Somerset
Printed in Italy by L.E.G.O. S.p.A.

ISBN 978 0 85369 792 3 (UK)
ISBN 978 1 58212 135 2 (USA)

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, without the prior written permission of the copyright holder.

The publisher makes no representation, express or implied, with regard to the accuracy of the information contained in this book and cannot accept any legal responsibility or liability for any errors or omissions that may be made.

A catalogue record for this book is available from the British Library

Benzalkonium Chloride

B

1 Nonproprietary Names

BP: Benzalkonium Chloride

JP: Benzalkonium Chloride

PhEur: Benzalkonium Chloride

USP-NF: Benzalkonium Chloride

2 Synonyms

Alkylbenzyltrimethylammonium chloride; alkyl dimethyl benzyl ammonium chloride; benzalkonii chloridum; BKC; *Hyamine 3500*; *Pentonium*; *Zephiran*.

3 Chemical Name and CAS Registry Number


Alkyldimethyl(phenylmethyl)ammonium chloride [8001-54-5]

4 Empirical Formula and Molecular Weight

The USP32–NF27 describes benzalkonium chloride as a mixture of alkylbenzyltrimethylammonium chlorides of the general formula $[C_6H_5CH_2N(CH_3)_2R]Cl$, where R represents a mixture of alkyls, including all or some of the group beginning with n -C₈H₁₇ and extending through higher homologs, with n -C₁₂H₂₅, n -C₁₄H₂₉, and n -C₁₆H₃₃ comprising the major portion.

The average molecular weight of benzalkonium chloride is 360.

5 Structural Formula



R = mixture of alkyls: n -C₈H₁₇ to n -C₁₈H₃₇; mainly n -C₁₂H₂₅ (dodecyl), n -C₁₄H₂₉ (tetradecyl), and n -C₁₆H₃₃ (hexadecyl).

6 Functional Category

Antimicrobial preservative; antiseptic; disinfectant; solubilizing agent; wetting agent.

7 Applications in Pharmaceutical Formulation or Technology

Benzalkonium chloride is a quaternary ammonium compound used in pharmaceutical formulations as an antimicrobial preservative in applications similar to other cationic surfactants, such as cetrimide.

In ophthalmic preparations, benzalkonium chloride is one of the most widely used preservatives,⁽¹⁾ at a concentration of 0.01–0.02% w/v. Often it is used in combination with other preservatives or excipients, particularly 0.1% w/v disodium edetate, to enhance its antimicrobial activity against strains of *Pseudomonas*.

In nasal,⁽²⁾ and otic formulations a concentration of 0.002–0.02% w/v is used, sometimes in combination with 0.002–0.005% w/v thimerosal. Benzalkonium chloride 0.01% w/v is also employed as a preservative in small-volume parenteral products. Benzalkonium chloride was also shown to enhance the topical penetration of lorazepam.⁽³⁾

Benzalkonium chloride is additionally used as a preservative in cosmetics.

8 Description

Benzalkonium chloride occurs as a white or yellowish-white amorphous powder, a thick gel, or gelatinous flakes. It is hygroscopic, soapy to the touch, and has a mild aromatic odor and very bitter taste.

9 Pharmacopeial Specifications

See Table I.

Table I: Pharmacopeial specifications for benzalkonium chloride.

Test	JP XV	PhEur 6.4	USP32–NF27
Identification	+	+	+
Characters	+	+	–
Acidity or alkalinity	–	+	–
Appearance of solution	+	+	–
Water	≤ 15.0%	≤ 10.0%	≤ 15.0%
Residue on ignition	≤ 0.2%	–	≤ 2.0%
Sulfated ash	–	≤ 0.1%	–
Water-insoluble matter	–	–	+
Foreign amines	–	+	+
Ratio of alkyl components	–	+	+
Petroleum ether-soluble substances	≤ 1.0%	–	–
Benzyl alcohol	–	≤ 0.5%	–
Benzaldehyde	–	≤ 0.15%	–
Chloromethylbenzene	–	≤ 0.05%	–
Assay (dried basis)			
of n -C ₁₂ H ₂₅	–	–	≥ 40.0%
of n -C ₁₄ H ₂₉	–	–	≥ 20.0%
of n -C ₁₂ H ₂₅ and n -C ₁₄ H ₂₉	–	–	≥ 70.0%
for total alkyl content	95.0–105.0%	95.0–104.0%	97.0–103.0%

10 Typical Properties

Acidity/alkalinity pH = 5–8 for a 10% w/v aqueous solution.

Antimicrobial activity Benzalkonium chloride solutions are active against a wide range of bacteria, yeasts, and fungi. Activity is more marked against Gram-positive than Gram-negative bacteria and minimal against bacterial endospores and acid-fast bacteria, *see* Table II. The antimicrobial activity of benzalkonium chloride is significantly dependent upon the alkyl composition of the homolog mixture.⁽⁴⁾ Benzalkonium chloride is ineffective against some *Pseudomonas aeruginosa* strains, *Mycobacterium tuberculosis*, *Trichophyton interdigitale*, and *T. rubrum*. However, combined with disodium edetate (0.01–0.1% w/v), benzyl alcohol, phenylethanol, or phenylpropanol, the activity against *Pseudomonas aeruginosa* is increased.⁽⁵⁾ Antimicrobial activity may also be enhanced by the addition of phenylmercuric acetate, phenylmercuric borate, chlorhexidine, cetrimide, or *m*-cresol.^(6,7) In the presence of citrate and phosphate buffers (but not borate), activity against *Pseudomonas* can be reduced. *See also* Sections 11 and 12. Benzalkonium chloride is relatively inactive against spores and molds, but is active against some viruses, including HIV.⁽⁸⁾ Inhibitory activity

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.